A simplified, efficient and streamlined workflow for your lab
BD MAX™ System family offers you a fully integrated, automated real-time PCR benchtop platform with a broad menu of molecular IVD and open-system test.
BD Respiratory Viral Panel for BD MAX™
Connect with us!
Fill in the form and you'll receive an info sheet on the BD MAX™ System.
The hidden burden of RSV
RSV is increasingly recognized as an important public health concern. It is the most frequent cause of bronchiolitis in infants and is responsible for more respiratory complications and casualties than COVID-19 or flu in children.
RSV also exacerbates pre-existing respiratory conditions in adults and may cause serious respiratory illness in the elderly.
- Globally, RSV may be responsible for 3.2 million hospitalizations and 118 200 deaths in children younger than 5 years.6
- In one study, 41% to 70% of hospitalizations in adults with influenza-like illness and 92% in adults with pneumonia were due to RSV.7
Introducing the BD MAX™ Respiratory Viral Panel Assay
Innovation that simplifies, Clinical differentiation that matters
SARS-Cov-2, influenza (flu), and respiratory syncytial virus (RSV) are 3 major viral respiratory infections with overlapping signs and symptoms making them difficult to differentiate without differential diagnostic testing.1,2
Co-infection with SARS-Cov-2 and other viral respiratory pathogens is not rare and increases disease severity and mortality risk compared to SARS-Cov-2 mono-infection.3,4 Testing is the only way to confirm the diagnosis.
The BD Respiratory Viral Panel for BD MAX™ System can help you to determine if a patient has COVID-19, the flu A +B and/or RSV infection.5
4 results, from 1 specimen, in 1 single run
With the BD Respiratory Viral Panel for BD MAX™ System, you can simultaneously detect and differentiate SARS-CoV-2, influenza A, influenza B, and/or RSV from one sample in a single run. The test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu season and speeds the time to diagnosis.
BD MAX™ Molecular Diagnostic System Family
A simplified, efficient and streamlined workflow for your lab
References
- NFID. Respiratory Syncytial Virus (RSV). Updated February 2022. Accessed 27 May 2022. https://www.nfid.org/infectious-diseases/rsv/
- CDC. Similarities and Differences between Flu and COVID-19. Updated January 2022. Accessed 27 May 2022. www.cdc.gov/flu/symptoms/flu-vs-covid19.htm.
- Musuuza JS et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.PLoS One. 2021;16(5):e0251170.
- Swets MC et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463–4.
- BD Respiratory Viral Panel for BD MAX™ System Package Insert (P0261)
- Shi T et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58.
- Ali A et al. Int J Infect Dis. 2020;90:170–80.
- Felder RA et al. J Lab Autom. 2014;19(5):468–73.
- Hirvonen JJ et al. Eur J Clin Microbiol Infect Dis. 2015;34(5):1005–9.
- CDC. Influenza SARS-CoV-2 Multiplex Assay. Updated November 2022. Accessed 27 April 2023. https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html
BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy